查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980753

全球抗高血壓藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Antihypertensive Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計抗高血壓藥物的市場規模將從 2025 年的 293.9 億美元成長到 2034 年的 430.8 億美元，2026 年至 2034 年的複合年成長率為 4.34%。

隨著全球高血壓患者人數的不斷增加，全球降血壓藥市場也穩定成長。高血壓是心血管疾病（包括心臟病和中風）的主要危險因子之一。人們對血壓管理和早期診斷重要性的認知不斷提高，推動了對有效降血壓藥物的需求。隨著文明病相關健康問題的日益普遍，長期高血壓治療的需求也顯著增加。

藥物技術的進步和各類藥物的廣泛應用正在推動市場成長。常用的降血壓藥包括BETA阻斷劑、鈣通道阻斷劑、利尿劑和血管張力素轉換酶抑制劑（ACE抑制劑）。醫療機構正在增加聯合治療的使用，以提高治療效果並降低併發症風險。此外，旨在擴大醫療服務覆蓋範圍和促進心血管健康的政府政策也進一步推動了降血壓藥物的使用。

未來幾年，隨著製藥公司持續增加對更有效、更安全藥物研發的投入，市場預計將持續成長。個人化醫療和創新藥物輸送系統也作為改善高血壓管理的潛在解決方案而備受關注。隨著全球心血管疾病負擔的持續加重，對降血壓藥物的需求預計將保持強勁。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球抗高血壓藥物市場：依治療方式分類

  • 市場分析、洞察與預測
  • 利尿劑
  • ACE抑制劑
  • 血管收縮素受體阻斷劑
  • BETA阻斷劑
  • 鈣離子通道阻斷劑
  • 腎素抑制劑
  • α受體阻斷劑
  • 血管擴張劑
  • 其他

第5章 全球抗高血壓藥物市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 原發性高血壓
  • 次發性高血壓

第6章：全球抗高血壓藥物市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物
  • 其他

第7章 全球抗高血壓藥物市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章 全球抗高血壓藥物市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Johnson & Johnson
    • Pfizer
    • Novartis
    • Merck & Co
    • Sanofi
    • AbbVie
    • AstraZeneca
    • Bayer
    • Takeda
    • Boehringer Ingelheim
    • Daiichi Sankyo
    • Sun Pharmaceutical Industries
    • Lupin
    • Torrent Pharmaceuticals
    • Noden Pharma
簡介目錄
Product Code: VMR112115233

The Antihypertensive Drugs Market size is expected to reach USD 43.08 Billion in 2034 from USD 29.39 Billion (2025) growing at a CAGR of 4.34% during 2026-2034.

The Global Antihypertensive Drugs Market is growing steadily due to the rising prevalence of hypertension worldwide. Hypertension is one of the leading risk factors for cardiovascular diseases, including heart attacks and strokes. Increasing awareness about the importance of blood pressure management and early diagnosis is driving the demand for effective antihypertensive medications. As lifestyle-related health conditions become more common, the need for long-term hypertension treatment is expanding significantly.

Pharmaceutical advancements and the availability of a wide range of drug classes are supporting market growth. Common antihypertensive medications include beta blockers, calcium channel blockers, diuretics, and ACE inhibitors. Healthcare providers are increasingly prescribing combination therapies to improve treatment outcomes and reduce the risk of complications. Additionally, expanding healthcare access and government initiatives promoting cardiovascular health are further boosting the adoption of antihypertensive drugs.

In the coming years, the market is expected to grow as pharmaceutical companies continue to invest in research and development for more effective and safer medications. Personalized medicine and innovative drug delivery systems are also gaining attention as potential solutions for better hypertension management. With the global burden of cardiovascular diseases continuing to rise, the demand for antihypertensive drugs is projected to remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy

  • Diuretics
  • Ace Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Calcium Channel Blockers
  • Renin Inhibitors
  • Alpha-Blockers
  • Vasodilators
  • Other

By Drug Type

  • Primary Hypertension
  • Secondary Hypertension

By Route Of Administration

  • Oral
  • Injectables
  • Other

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

COMPANIES PROFILED

  • Johnson Johnson, Pfizer, Novartis, Merck Co, Sanofi, AbbVie, AstraZeneca, Bayer, Takeda, Boehringer Ingelheim, Daiichi Sankyo, Sun Pharmaceutical Industries, Lupin, Torrent Pharmaceuticals, Noden Pharma
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Therapy
  • 4.2. Diuretics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Ace Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Angiotensin Receptor Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Renin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Alpha-Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.9. Vasodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.10. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Type
  • 5.2. Primary Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Secondary Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Therapy
    • 8.2.2 By Drug Type
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Therapy
    • 8.3.2 By Drug Type
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Therapy
    • 8.4.2 By Drug Type
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Therapy
    • 8.5.2 By Drug Type
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Therapy
    • 8.6.2 By Drug Type
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTIHYPERTENSIVE DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Johnson & Johnson
    • 10.2.2 Pfizer
    • 10.2.3 Novartis
    • 10.2.4 Merck & Co
    • 10.2.5 Sanofi
    • 10.2.6 AbbVie
    • 10.2.7 AstraZeneca
    • 10.2.8 Bayer
    • 10.2.9 Takeda
    • 10.2.10 Boehringer Ingelheim
    • 10.2.11 Daiichi Sankyo
    • 10.2.12 Sun Pharmaceutical Industries
    • 10.2.13 Lupin
    • 10.2.14 Torrent Pharmaceuticals
    • 10.2.15 Noden Pharma